San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
Professor Jack Johnson was nominated with 22 letters of support from current and former trainees.
The Boger lab has made a powerful analog of vancomycin that is effective against MRSA and other disease-causing bacteria.
On the occasion of positive new data for RPC1063, Professor Hugh Rosen shares his perspective on the drug candidate, which was initially discovered, synthesized and developed at TSRI.
“It has added power to many of the technologies we already have on campus,” says Professor Luc Teyton.
UCSD scientists found a twist in how bad news affects the brain, and depression therapy may benefit.
SGB Inc., a local agricultural biotech company, has closed an $11 million Series C financing round to help drive the commercial roll out of its hybrid crops — a low-cost and sustainable plant-based option for fuel, energy-producing biomass and protein in animal feed.
Drug developer Lpath is selling $12.5 million of stock in a direct offering.
Team Sanford-Burnham is gearing up for the big Pedal the Cause San Diego ride this Saturday and Sunday (Sept. 20 & 21). Pedal the Cause San Diego, the only multiday cycling fundraiser to support cancer research in San Diego, provides critical funding to the community’s three NCI-designated cancer centers.
Researchers at the University of California, San Diego School of Medicine, University of Pittsburgh and elsewhere describe the first human tests of using a perfluorocarbon (PFC) tracer in combination with non-invasive magnetic resonance imaging (MRI) to track therapeutic immune cells injected into patients with colorectal cancer.
WASHINGTON–(BUSINESS WIRE)–The breakout session program for BIO’s ninth annual Pacific Rim Summit on Industrial Biotechnology and Bioenergy, to be held in San Diego in December 2014, will focus on technology commercialization.